Wells Fargo & Company MN continued to hold its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,038 shares of the biotechnology company’s stock at the end of the first quarter. Wells Fargo & Company MN owned approximately 0.09% of Anavex Life Sciences Corp. worth $207,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. State Street Corp boosted its stake in Anavex Life Sciences Corp. by 27.2% in the fourth quarter. State Street Corp now owns 391,065 shares of the biotechnology company’s stock worth $1,549,000 after buying an additional 83,716 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Anavex Life Sciences Corp. during the fourth quarter worth $151,000. Finally, Edge Wealth Management LLC bought a new stake in shares of Anavex Life Sciences Corp. during the first quarter worth $230,000. Institutional investors own 22.88% of the company’s stock.
Shares of Anavex Life Sciences Corp. (AVXL) traded down 5.08% during midday trading on Tuesday, reaching $3.74. 461,567 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $4.97 and its 200 day moving average price is $5.44. Anavex Life Sciences Corp. has a 52-week low of $2.43 and a 52-week high of $6.64. The firm’s market capitalization is $154.75 million.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). On average, equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.37) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/09/wells-fargo-company-mn-has-207000-position-in-anavex-life-sciences-corp-nasdaqavxl-updated-updated.html.
Several equities research analysts have commented on AVXL shares. Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Wednesday, April 12th. Noble Financial reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Sunday, May 14th. Maxim Group set a $15.00 price target on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research report on Monday, May 22nd. Finally, ValuEngine cut shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $11.94.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
